Brain cancer chemo delivered directly: a safety first
NCT ID NCT03154996
First seen May 08, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This early-stage study tested whether it is safe to deliver the chemotherapy drug topotecan directly into the brain over several days for people with recurrent high-grade gliomas, a serious type of brain cancer. Only 5 participants were enrolled. The main goal was to find a dose that causes no more than mild side effects, and researchers also looked for signs that the drug was reaching the tumor and shrinking it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.